(Q51363916)

English

The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients.

scientific article published on 6 January 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22171692

The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients. (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22171692

type 2 diabetes

0 references

1 reference

based on heuristic

2

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22171692

Gian Paolo Fadini

object named as

Gian P Fadini

1

0 references

author name string

L Menegazzo

3

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22171692

S V de Kreutzenberg

4

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22171692

A Avogaro

5

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22171692

publication date

6 January 2012

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22171692

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22171692

14

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22171692

6

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22171692

518-522

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22171692

Pharmacological management of type 2 diabetes: the potential of incretin-based therapies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01550.X

21 January 2018

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01550.X

21 January 2018

Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01550.X

21 January 2018

Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01550.X

21 January 2018

Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01550.X

21 January 2018

Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01550.X

21 January 2018

Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01550.X

21 January 2018

Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01550.X

21 January 2018

Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01550.X

21 January 2018

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01550.X

21 January 2018

A Fischer rat substrain deficient in dipeptidyl peptidase IV activity makes normal steady-state RNA levels and an altered protein. Use as a liver-cell transplantation model

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01550.X

21 January 2018

Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01550.X

21 January 2018

Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01550.X

21 January 2018

Gastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase-4 activity in obese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01550.X

21 January 2018

Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01550.X

21 January 2018

Incretin secretion and serum DPP-IV activity in Korean patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01550.X

21 January 2018

Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01550.X

21 January 2018

Physiological and Pharmacological Mechanisms through which the DPP-4 Inhibitor Sitagliptin Regulates Glycemia in Mice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01550.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2011.01550.X

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22171692

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22171692

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51363916&oldid=1727088292"